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Abstract
Background: Microarray technology has been previously used to identify genes that are differentially expressed between 
tumour and normal samples in a single study, as well as in syntheses involving multiple studies. When integrating results from 
several Affymetrix microarray datasets, previous studies summarized probeset-level data, which may potentially lead to a loss 
of information available at the probe-level. In this paper, we present an approach for integrating results across studies while 
taking probe-level data into account. Additionally, we follow a new direction in the analysis of microarray expression data, 
namely to focus on the variation of expression phenotypes in predeﬁ  ned gene sets, such as pathways. This targeted approach 
can be helpful for revealing information that is not easily visible from the changes in the individual genes.
Results: We used a recently developed method to integrate Affymetrix expression data across studies. The idea is based on 
a probe-level based test statistic developed for testing for differentially expressed genes in individual studies. We incorpo-
rated this test statistic into a classic random-effects model for integrating data across studies. Subsequently, we used a gene 
set enrichment test to evaluate the signiﬁ  cance of enriched biological pathways in the differentially expressed genes identi-
ﬁ  ed from the integrative analysis. We compared statistical and biological signiﬁ  cance of the prognostic gene expression 
signatures and pathways identiﬁ  ed in the probe-level model (PLM) with those in the probeset-level model (PSLM). Our 
integrative analysis of Affymetrix microarray data from 110 prostate cancer samples obtained from three studies reveals 
thousands of genes signiﬁ  cantly correlated with tumour cell differentiation. The bioinformatics analysis, mapping these 
genes to the publicly available KEGG database, reveals evidence that tumour cell differentiation is signiﬁ  cantly associated 
with many biological pathways. In particular, we observed that by integrating information from the insulin signalling path-
way into our prediction model, we achieved better prediction of prostate cancer.
Conclusions: Our data integration methodology provides an efﬁ  cient way to identify biologically sound and statistically 
signiﬁ  cant pathways from gene expression data. The signiﬁ  cant gene expression phenotypes identiﬁ  ed in our study have 
the potential to characterize complex genetic alterations in prostate cancer.
Keywords: pathway enrichment analysis, meta-analysis, data synthesis, probe-level test, prostate cancer, random effect models.
1. Introduction
Many statistical methods have been developed and applied to the molecular classiﬁ  cation of cancers 
using gene expression proﬁ  ling data. A popular paradigm for this kind of analysis is that a set of differ-
entially expressed prognostic genes are ﬁ  rst selected using a univariate method, such as the t-test, then 
a classiﬁ  er is built on the selected genes (Golub et al. 1999; Dudoit et al. 2002; Ramaswamy et al. 2003; 
Tan et al. 2005b). There are some limitations to these methods: (1) they are for the most part developed 
purely based on computational or algorithmic grounds without using prior biological knowledge, such 
as pathway information, which is richly accumulated in the medical literatures and relevant public data-
bases (Wei and Li, 2006); (2) it is hard to interpret individual genes on a list with many signiﬁ  cant genes. 
Moreover, when several studies address the same question, these lists may identify very different sets Cancer Informatics 2006: 2 290
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of genes. For example, Sorlie et al. (2001), van’t 
Veer et al. (2002) and Ramaswamy et al. (2003) 
made attempts to predict survival of breast cancer 
patients, but the sets of survival-related genes 
identiﬁ  ed in these studies had only a few genes in 
common. There are only 17 genes shared between 
the list of 456 genes from Sorlie et al. and the list 
of 231 genes from van’t Veer et al. and only 2 genes 
appeared in common between Sorlie et al. and 
Ramaswamy et al. Ein-Dor et al. (2005) reanalyzed 
the van t’Veer dataset in an attempt to explain the 
inconsistencies between lists from different studies. 
They found that the predictive power of several 
lists of survival-related genes, generated from the 
same data set, is similar and quite good, although 
the relative rankings of genes in different lists, on 
the basis of correlation with survival, change 
greatly. Moreover, membership in these prognostic 
lists is not necessarily indicative of the gene’s 
importance in cancer pathology. Since cancer is 
‘caused’ or inﬂ  uenced by multiple gene variations 
more often than by a single gene, it is more reason-
able to focus on pathways than on individual genes 
(Vogelstein and Kinzler, 2004). Therefore, recent 
focus has been on methods useful for discovering 
signiﬁ  cant biological pathways which contribute 
to cancer. One of these innovative approaches is 
gene set enrichment analysis (GSEA) that focuses 
on evaluating gene expression data at the level of 
gene sets (Mootha et al. 2003; Subramanian et al. 
2005). Starting with predeﬁ  ned gene sets belonging 
to particular pathways or sharing the same gene 
function categories, the GSEA method evaluates 
whether the elements of a given gene set tend to 
occur toward the top (or bottom) of a ranked gene 
list, according to their differential expression 
between two classes (such as normal and cancer 
samples) measured by signal to noise ratios (SNR) 
(Golub et al. 1999) or similar metric.
Another challenge of microarray data analysis 
is that although individual microarray studies can 
be highly informative in identifying individual 
genes (e.g. van’t Veer et al.’s 2002) or signiﬁ  cant 
biological pathways (e.g. Mootha et al. 2003), it 
is still difﬁ  cult to make a direct comparison among 
the results obtained by different groups addressing 
the same biological problem, since laboratory 
protocols, microarray platforms and analysis 
techniques used in each study may not be identical. 
Moreover, most individual studies have relatively 
small sample sizes, and hence prediction models 
trained in individual studies by using cross-
validation are prone to over-ﬁ  tting, leading to 
prediction accuracies that may be less robust and 
lack generalizability (Cruz and Wishart, 2006). 
Recent studies show that systematic integration 
of gene expression data from different sources can 
increase statistical power to detecting differen-
tially expressed genes while allowing for an 
assessment of heterogeneity (Rhodes et al. 2002; 
Choi et al. 2003; Hu et al. 2005; Stevens and 
Doerge, 2005), and may lead to more robust, 
reproducible and accurate predictions. 
In general, the approaches used for integration 
across studies fall into three broad categories. In 
the ﬁ  rst approach, each data set is normalized and 
standardized and then the datasets are directly 
combined to appear to be a single experiment 
(Wang et al. 2006). This method is simple and can 
sometimes work well, but it cannot capture or 
appropriately cope with any inter-laboratory 
differences, which can be quite substantial even 
within the same technology (Irizarry et  al. 2005). 
Variation in patient populations, environments, or 
lab conditions means that two studies may have 
different gene expression patterns, and a combined 
analysis ignores this source of variability. The 
second approach combines p-values from indi-
vidual studies to estimate an overall p-value for 
each gene across all studies (Rhodes et al. 2002). 
Since in this case the method chosen to combine 
results across studies is based on the statistical 
confidence measure (the p-value), not on the 
expression levels, this strategy avoids direct 
comparisons of data, and hence avoids issues 
related to cross-platform differences in measure-
ment or normalization. However, Hu et al. (2006a) 
showed that combining only p-values, while useful 
in obtaining more precise estimates of signiﬁ  cance, 
may not indicate the direction of signiﬁ  cance (e.g. 
up-or down-regulation). Moreover, a signiﬁ  cant 
result from a large combined sample, based on the 
Fisher test combining p-values, does not neces-
sarily correspond to a biologically important effect 
size (Rhodes et al. 2002). The third approach is 
based on integrating microarray expression values 
using random effect or ﬁ  xed effect hierarchical 
models (Choi et al. 2003; Hu et al. 2005), in which 
the effect size estimate of a gene is used to measure 
the magnitude of treatment effect in a given study. 
Choi et al. (2003) demonstrated that their random 
effects model can lead to the discovery of small 
but consistent expression changes with increased 
sensitivity and reliability. The advantage of a 291
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random effects model is that variability between 
studies is estimated and taken into account.
Previous applications of random effects or ﬁ  xed 
effects models to integrate the results of experi-
ments performed using the Affymetrix technology 
have mainly focused on summarized probeset-level 
gene expression data (e.g. Hu et al. 2005). A 
probeset consists of 11–20 probe pairs where a probe 
is a short sequence of nucleotides in the coding 
region of the gene; the summary is a single repre-
sentative measure of probeset expression. However, 
there may be additional information at the probe 
level that is lost by combining the probeset results 
into a single number (Bolstad, 2004; Elo et al. 
2005). Some recent studies showed that methods 
based on probe-level models have much higher 
power to detect differentially expressed genes than 
summarized probeset-level approaches, in either 
individual studies (Bolstad, 2004), or across studies 
(Elo et al. 2005). For example, Bolstad (2004) devel-
oped a probe-level based test statistic for detecting 
differentially expressed genes in an individual 
study, in which parameters are estimated that 
account for variability across arrays and across 
probes. In the same vein, Elo et al. (2005) ﬁ  rst calcu-
lated effect size for each probe in a given probeset, 
then obtained a summary (probeset-level) estimate 
of effect size estimate by averaging the probe-level 
estimates over the probes within each probe set.
The objectives of this study are twofold: The 
ﬁ  rst is to demonstrate how to incorporate Bolstad’s 
probe-level -based test statistics into a random 
effects model (Choi et al. 2003; Hu et al. 2005) in 
order to integrate prostate cancer microarray expres-
sion data across studies; The second is to identify 
signiﬁ  cant biological pathways from the integrative 
analysis and evaluate the power of the identiﬁ  ed 
pathways for predicting prostate cancer. We compare 
the advantages and disadvantages of the probe-level 
based model with the traditional probeset-level 
based model from these two points of view.
2. Data sets and pre-processing
Data on gene expression in prostate tumours and 
controls were obtained from Welsh et al. (2001), 
Singh et al. (2002), LaTulippe et al. (2002), and 
Stuart et al. (2004). The datasets will be referred 
to by the name of the ﬁ  rst author. All these datasets 
are either publicly available or obtainable upon 
request. Information about these datasets, such as 
the microarray platform, the number of samples 
available, and the data sources, is listed in
Table 1. Using leave-one-out cross-validation 
(LOOCV), excellent predictive accuracy has been 
obtained for the Singh data based on both the K-
nearest neighbour (KNN) model (Singh et al. 2002) 
and the top-scoring pair (TSP) algorithm (Tan
et al. 2005a and Xu et al. 2005). In order to compare 
our predictive performance with those results, we 
randomly divided the Singh data into a training set 
and a testing set; each of these two datasets includes 
25 normal samples and 26 cancer samples. There-
fore, the Welsh data, the LaTulippe data, and the 
Singh training data were used to develop our 
predictive models (the “training data”), and the 
remaining data sets were used for testing the 
models (the “testing” data). First, the training data 
were used to identify differentially expressed genes 
and signiﬁ  cant biological pathways for building 
models to predict primary prostate cancer. The 
predictive power of the selected genes and path-
ways were then evaluated using the testing data.
Since the Affymetrix microarray data sets in 
this meta-analysis were analyzed in two ways (at 
the probe-level and at the probeset-level), we 
normalized the probe-level perfect match (PM) 
and mismatch (MM) densities using the quantile 
normalization method (Bolstad et al. 2003) within 
each dataset. For the probeset-level model anal-
ysis, we then converted the quantile-normalized 
probe level data to a single expression measure 
for each probe set and each dataset, using the 
robust multi-array average (RMA) algorithm 
(Irizarry et al. 2003). 
3. Methods
3.1 Modelling effect sizes to integrate 
gene expression patterns across 
studies
We used a random effect model of effect size 
measures to integrate gene expression patterns 
across studies (Choi et al. 2003; Hu et al. 2005). 
There are different ways to measuring effect size 
yg for gene g in any individual study. Here we 
present two methods: One is based on summarized 
probeset-level data (Choi et al. 2003; Hu et al. 
2005); another is the one we recently developed 
(Hu et al. 2006b), which is based on the Affyme-
trix probe-level data. In order to simplify the 
discussion, we only consider a comparison of two Cancer Informatics 2006: 2 292
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groups: treatment (t) and control (c) groups in a 
study.
Let nt, nc and n = nt + nc denote the number of 
treatment, control and total samples in the study, 
respectively.
3.1.1 Measuring effect size using
probe-level Affymetrix microarray data
The probe-level based effect size measure is derived 
from a recently proposed probe-level based test 
statistic for detecting differentially expressed genes 
(Bolstad, 2004; Bolstad, 2005). A probe-level 
model can be deﬁ  ned as follows: For each dataset 
assume that there are I probes for each probeset and 
n arrays. A probe-level model can be ﬁ  tted using
  pmij = mmij + αi + βj + εij (1) 
where i = 1, …, I and j = 1, …, n, pmij and mmij 
are the pre-processed (normalized) log2 of the 
perfect match and mismatch intensities, respec-
tively, αi represent probe effects and βj are array 
effects (on the log2 expression scale). The error is 
assumed to have mean zero and Var(εij) = σ
2. To 
make the model identifiable, the constraint
Σi
I
=1αi =  0 is used. Let 

β  be the estimated array 
effects and 

Σbe the portion of the estimated
variance-covariance matrix related to β from ﬁ  tting
the probe-level model (1). Let V be a contrast 
vector where element j of V is 
1
nc if array j is in 
group c, or  −1
nt  if array j is in group t. Then, a probe-
level based t-test statistic (tpl) can be deﬁ  ned as
  t
V
Vd i a g V
pl =
′
′


β
() Σ
 (2)
Here diag(

Σ) means that the off-diagonal elements 
of 

Σ are zero. This test statistic can be used to 
detect differential expression between the control 
group (c) and the treatment group (t). For each 
study, we deﬁ  ne an effect measure for gene g by 
transforming the probe-level based t-statistic in (2) 
as follows:
  yt
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*
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Table 1. Training and test data sets.
Data Set  Platform  Number  Number  Number  Reference  Source of 
    of Probe  of Normal  of Cancer    Raw Data
   Sets/Spots  Samples  Samples
Training  Affymetrix  12600  25  26  Singh et al.  Supplement
Sets (HG_U95Av2)        (2002)
[1]
  Affymetrix   12626  8  25  Welsh et al.  Author
 (HG_U95Av2)       (2001)
[2]
  Affymetrix  12626  3  23  LaTulippe et al.  GEDP
[3]
 (HG_U95Av2)        (2002)
Testing  Affymetrix  12600  25  26  Singh et al.  Supplement
Sets (HG_U95Av2)        (2002)
[1]
  Affymetrix  12625  50  38  Stuart et al.  GEO
[4]
  (HG_U95Av2)       (2004)
[1] The Singh data set was randomly divided into a training set (51 arrays) and a testing set (51 arrays)
[2] The numbers of normal and cancer samples shown in original papers are 9 and 24 respectively. The author suggested that we treat the 
data as 8 normal samples and 25 cancer samples when they sent us their raw data (CEL ﬁ  les)
[3] The Gene Expression Data Portal (GEDP), National Cancer Institute
[4] GEO: Gene Expression OmnibusCancer Informatics 2006: 2 293
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3.1.2 Measuring effect size using summarized 
probeset-level Affymetrix microarray data
A corresponding effect size for summarized 
probeset-level Affymetrix microarray data can be 
deﬁ  ned as
  y
xx
s
g
gt gc
g
pool =
− ()  (5)
where  xgt and  xgc  are the sample means of gene 
expression values for gene g in treatment group t 
and control group c of a given study, respectively, 
and where sg
pool is the pooled standard deviation 
(Hu et al. 2005). For a study with n samples, an 
approximately unbiased estimation of 
 yg is given 
by 
 yg = yg – 3* yg  /(4n – 9) and its variance sg
2 can 
be estimated by
  ˆ
ˆ
()
s
nn
y
nn
g
tc
g
tc
2
2
11
2
=+
⎛
⎝ ⎜
⎞
⎠ ⎟ +
+
 (6) 
This deﬁ  nition of effect size is widely adopted in the 
meta-analysis literature (Hedges and Olkin 1985).
3.1.3 Integrating effect sizes across studies
For each gene g, we have estimated its effect size 
ygm(m = 1, …, M) in M studies using equation (3) 
for probe-level analysis and using equation (5) for 
probeset-level analysis. A detailed description of 
the modelling techniques for integrating micro-
array data across studies can be found in Hu et al. 
2005. Let μg denote the overall mean effect size of 
gene g in all M studies and sgm
2  be the effect size 
variance of gene g, measuring the sampling error 
for the m
th study. Using a random effects model 
(Choi et al. 2003; Hu et al. 2005), the meta-analysis 
estimate for μg can be calculated as:
  ˆ μg
m
M
mg m
m
M
m
wy
w
=
=
=
Σ
Σ
1
1
 (7)
where the weights are given by wm = (sgm
2
+ τ
2)
–1 and 
τ
2 is the between-study variability (Choi et al. 2003). 
The variance of this estimator is obtained by
  Var
w
g
m
M
m
( ˆ ) μ =
=
1
1 Σ  (8)
A test statistic to evaluate the treatment effect of gene 
g across all m studies can then be computed as
  zg
g
g
=
ˆ
var( ˆ )
μ
μ
 (9)
We evaluated the statistical signiﬁ  cance of gene g 
by calculating the p-value corresponding to the
z statistic, then we estimated the false discovery 
rates (FDR) for each signiﬁ  cance level, to take into 
account the number of tests performed (Benjamini 
and Hochberg, 1995). We refer the approach of 
estimating zg using the probe-level based test 
statistic as the Probe-Level Model (PLM) and we 
refer to the method based on the probeset-level test 
statistic as the ProbeSet-Level Model (PSLM). 
3.2 Pathway-based learning models 
for predicting prostate cancer
3.2.1 Selecting gene sets
Pathway-based models assume that members in a 
set of genes are known to belong to the same 
pathway or have the same function. Such prior 
biological knowledge can be derived from many 
public sources, such as Gene Ontology (GO) 
(Ashburner et al. 2000) or the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) (Kanehisa and 
Goto, 2002). The former is a database of controlled 
vocabulary gene annotations describing the biolog-
ical processes, molecular functions and cellular 
localizations of genes, while the latter is a pathway 
resource, which contains graphical representations 
of cellular processes. Since pathways involving 
multiple processes and functions are not well 
represented in GO, we deﬁ  ned the gene sets used 
in this study based on KEGG.
3.2.2 Mapping differentially expressed 
probes (genes) to predeﬁ  ned gene sets
Using the probe identiﬁ  ers in the Affymetrix anno-
tation table for HGu95Av2 GeneChips (obtained 
from http://www.affymetrix.com/support/technical), 
we mapped the selected differentially expressed 
probes (FDR-adjusted p-values< = 0.05) to KEGG 
pathways via LocusLink identiﬁ  ers using the func-
tion ‘probes2Path’ in the Category package of Cancer Informatics 2006: 2 294
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bioconductor (www.bioconductor.org). It should be 
noted that some LocusLink identiﬁ  ers may not be 
mapped to any known pathways in KEGG due to 
the limited number of pathways in the database.
3.2.3 Evaluating signiﬁ  cance
for mapped gene sets
There are different ways to test for an excess of 
differentially expressed genes in the same pathway. 
We used the “gene set enrichment test” implemented 
in the limma R package (Smyth, 2004). The 
approach uses the Wilcoxon signed rank test to 
compute a p-value to test the hypothesis that a 
given mapped gene set tends to be more highly 
ranked than would be expected by chance. The 
ranking must be based on a t-like test statistic, and 
here we used the z statistics for PLM and PSLM 
described in Section 3.1. The test is essentially a 
streamlined version of the GSEA approach intro-
duced by Mootha et al. (2003).
3.2.4 Pathway-based learning models using 
support vector machines (SVMs) 
For each signiﬁ  cant biological pathway identiﬁ  ed 
from the analysis in Section 3.2.3, we built two 
simple linear kernel function-based SVM classiﬁ  -
cation models, for PLM and PSLM, respectively, 
using the training data and evaluated their perfor-
mance using the testing data (see Table 1). A 
detailed description of the mathematics behind 
SVM can be found in (Vapnik, 1998). In this study, 
we used the SVM algorithm implemented in the 
e1071 package in the R Project for Statistical 
Computing (http://www.r-project.org/). The perfor-
mance of the pathway-based SVM model was 
evaluated based on prediction accuracy, namely, 
the proportion of correctly predicted samples out 
of all samples in a given testing set.
4. Results
4.1 Genes showing signiﬁ  cant 
expression patterns with tumour 
differentiation
We identiﬁ  ed 12,600 common probesets across the 
three training sets as shown in Table 1, and PLM 
and PSLM were applied to the common probesets. 
Figure 1 shows the number of differentially 
expressed genes identiﬁ  ed by integrative analysis 
of the common expression patterns in the three 
training sets for different thresholds of FDR-
adjusted p-values. It can be seen that a large number 
of differentially expressed genes were obtained 
using these two models. For example, by setting a 
threshold of FDR = 0.05, we obtained 1350 differ-
entially expressed genes using PLM and 917 differ-
entially expressed genes using PSLM. In general, 
the PLM method identiﬁ  ed more differentially 
expressed genes than the PSLM approach for FDR 
thresholds between 0.00 and 0.05 (Fig. 1). More-
over, the absolute values of the z statistics (a 
measure of signiﬁ  cance) for genes identiﬁ  ed by 
PLM are much larger than those identified by 
PSLM. The sets of signiﬁ  cantly expressed genes, 
for FDR-adjusted p-values less than 0.05, are 
provided in supplementary Tables 1 and 2 for PLM 
and PSLM, respectively. There are 672 shared 
genes in these two lists. A close examination of the 
top 50 gene expression signatures in the gene lists of 
supplementary Tables 1 and 2 indicates more previ-
ously known functionally important genes at the 
top of the PLM list. For example, HPN, which was 
identiﬁ  ed only by PLM, is functionally linked to 
the hepatocyte growth factor/MET pathway and 
has been found to be highly expressed in prostate 
tumours (Singh et al. 2002). This gene was also 
included in the 16-gene K-nearest neighbour 
(KNN) model of Singh et al. (2002), and in the TSP 
model of Xu et al. (2005). Another gene on the top 
of PLM list, FASN, is a known tumour marker; 
Welsh et al. (2001) found strong and speciﬁ  c immu-
nopositivity in malignant epithelium in all of 10 
cancer patients when they stained tissue sections 
with a monoclonal antibody against FASN.
We evaluated the discriminative power of the 
differentially expressed genes in Supplementary 
Tables 1 and 2 using linear kernel function-based 
SVM models built on the training datasets, and 
varying the number of predictors between 1 and 
all selected genes, and the predictive accuracy 
stopped improving after 50 genes. The perfor-
mance of these predictors was tested separately on 
the testing data portion of Singh et al. (2002)’s 
data, and on an independent dataset (Stuart et al. 
2004). The classiﬁ  cation accuracies are presented 
in Figures 2(a) for the Singh data, and 2(b) for the 
Stuart data. Models were built and tested separately 
for each number of genes included as predictors. 
Genes obtained from the meta-analyses of the 
training sets were ranked by the adjusted p-values 
for inclusion in the prediction models, so that, for Cancer Informatics 2006: 2 295
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example, the models containing 10 genes used the 
10 genes with the smallest adjusted p-values.
For the Singh data, genes identiﬁ  ed by PLM 
usually have better prediction accuracies than those 
identiﬁ  ed by PSLM. The best prediction accuracy 
is 94.1% using 17 genes identiﬁ  ed by PLM and 
90.2% using 49 genes selected by PSLM. For the 
Stuart data, PLM also outperforms PSLM. Our best 
accuracies for the Stuart data are 81.8% for PLM 
model using 40 genes and 68.2% using 27 genes 
for PSLM.
4.2 Signiﬁ  cantly enriched KEGG
pathways for differentially expressed 
genes with tumour differentiation 
We tested both sets of signiﬁ  cantly expressed genes 
(shown in Supplementary Tables 1 and 2) for iden-
tifying signiﬁ  cantly enriched KEGG pathways. We 
identiﬁ  ed 129 and 116 pathways showing evidence 
for enrichment with p-values less than 0.01, using 
PLM and PSLM, respectively. There are 113 shared 
pathways in these two sets of pathways. Tables 2 
and 3 show the top 20 signiﬁ  cantly enriched path-
ways identiﬁ  ed in each of these two lists. These 
top pathways are all highly signiﬁ  cantly enriched 
by both methods of analysis. Among the top 20 
pathways, 15 are in common across the two 
methods for integrative analysis.
Prediction models using SVM were developed 
using the pathway-identified sets, and strong 
predictive power can be seen in Tables 2 and 3 for 
many of the pathways and for both integrative 
methods. However, the predictive power appears 
better for models built on the PLM integrative 
analysis than the PSLM analysis. For example, we 
found the insulin signalling pathway has consis-
tently strong predictive power in the two test sets 
using either PLM or PSLM. Using PLM, this 
pathway, including 28 genes, has prediction accu-
racy of 92.2% for the Singh data and 79.5% for the 
Stuart data. In PSLM, however, this pathway now 
represented by only 21 genes, has only 80.4% and 
73.9% classiﬁ  cation accuracy for the Singh data 
and the Stuart data, respectively. 
5. Discussion
In this study, we used a recently developed method 
to integrate Affymetrix expression data across 
Figure 1. Number of differentially expressed genes as a function of false discovery rate (FDR) thresholds.
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Figure 2. Predictive accuracy of the SVM models, as a function of the number of differentially expressed 
genes used for prediction: (a) Singh testing data; (b) Stuart testing data.
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studies (Hu et al. 2006b). The idea is based on a 
probe-level based test statistic developed for testing 
differentially expressed genes in individual studies 
(Bolstad, 2004; Bolstad, 2005). We incorporated 
this test statistic into a classic random-effects model 
for integrating data across studies. When this new 
method was compared with a more traditional 
method to summarize probeset-level test statistics 
across different studies (Choi et al. 2003), the sets 
of genes and pathways identiﬁ  ed by PLM were more 
statistically signiﬁ  cant and biologically sound. The 
PLM identiﬁ  ed more differentially expressed genes 
and pathways than the PSLM. Moreover, the PLM 
identiﬁ  ed some biologically validated genes contrib-
uting to prostate cancer, which have not been 
detected by the PSLM. Using SVM-based classi-
ﬁ  ers, the genes and pathways identiﬁ  ed by PLM 
have better predictive power in most cases than those 
identiﬁ  ed by PSLM.
Our models show competitive predictive capa-
bility when compared to the previous analyses of 
these data. For example, Singh et al. (2002) 
selected 1–256 genes by using the signal-to-noise 
statistic (Golub et al. 1999) and measured differ-
ential expression between normal and tumour 
prostate samples. For each of the 256 sets of genes, 
they built a KNN classiﬁ  er and estimated predic-
tion accuracy using leave-one-out cross-validation 
(LOOCV). The range of the prediction accuracy 
was 86%–92%, corresponding to between 4–256 
genes. Tan et al. (2005a) showed the predictive 
accuracy for 7 classiﬁ  ers (TSP, K-TSP, C4.5 deci-
sion tree (DT), Naïve Bayes (NB), KNN, SVM 
and prediction analysis of microarrays (PAM)) 
based on LOOCV for the Stuart dataset. Their best 
accuracies were 67.6%, 75.0%, 64.8%, 73.9%, 
69.3%, 76.1% and 79.6%, respectively. Some 
studies show that LOOCV overestimates accuracy 
relative to accuracies based on 10 fold cross-
validation (Ambroise and McLachlan, 2002). 
However, other studies also pointed out that clas-
siﬁ  cation accuracy, when determined by cross-
validation using the same data set from which the 
class predictor was derived, may be overestimated 
(see supplementary materials in Lapointe et al. 
2004).
Traditional microarray-based cancer prediction 
approaches use only differentially expressed genes 
as biomarkers to discriminate classes of cancer and 
normal samples. However, a large proportion of 
Table 2. The top 20 signiﬁ  cantly enriched pathways for the set of signiﬁ  cantly differentially-expressed genes 
identiﬁ  ed using PLM (Supplementary Table 1), together with their predictive accuracies in the test datasets.
Pathway  p-value  # of   Accuracy of    Accuracy of    Pathway Name
ID    Genes*  Singh testing   Stuart testing
    data data   
04810  0  33  0.824  0.761  Regulation of actin cytoskeleton
04910  0  28  0.922  0.795  Insulin signaling pathway
00230 0  29  0.686  0.591  Purine  metabolism
04010  0  46  0.745  0.818  MAPK signaling pathway
04020  0  29  0.824  0.568  Calcium signaling pathway
04510 0  35  0.804  0.693  Focal  adhesion
00190 5.55E-16  23  0.804  0.67  Oxidative  phosphorylation
04514  8.88E-16  23  0.843  0.648  Cell adhesion molecules (CAMs)
00240 1.78E-14  21  0.745  0.557  Pyrimidine  metabolism
04070  3.44E-14  20  0.765  0.705  Phosphatidylinositol signaling system
01430 1.25E-13  19  0.843  0.739  Cell  Communication
04060 5.75E-13  18  0.765  0.682  Cytokine-cytokine  receptor  interaction
04530 2.93E-12  17  0.784  0.602  Tight  junction
00330  4.09E-12  17  0.882  0.739  Arginine and proline metabolism
04310  1.01E-11  16  0.725  0.682  Wnt signaling pathway
00480 2.40E-11  16  0.843  0.67  Glutathione  metabolism
04540 4.48E-11  15  0.686  0.818  Gap  junction
04720 4.61E-11  15  0.765  0.773  Long-term  potentiation
04670  4.96E-11  15  0.824  0.705  Leukocyte transendothelial migration
04512 5.93E-11  15  0.745  0.795  ECM-receptor  interaction
* The number of genes used in building models for prostate cancer prediction.Cancer Informatics 2006: 2 298
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such genes are irrelevant and functional correla-
tions among those genes are ignored. Since the 
genes with the best discriminative power are likely 
to correspond to a limited set of biological func-
tions or pathways, it is rational to focus on these 
key functional expression patterns/pathways for 
cancer prediction. This approach may then provide 
clues as to the types of biological processes that 
underlie the expression patterns of sets of genes. 
We found several pathways deﬁ  ned in the KEGG 
database could accurately discriminate prostate 
cancer samples from control samples. Although 
the best performance of the pathway-based predic-
tion models (e.g. 92.2% prediction accuracy was 
obtained for Singh testing data using 28 genes in 
insulin signalling pathway identiﬁ  ed by PLM) is 
slightly worse than the best prediction accuracy 
based solely on the top genes (e.g. 94.1% predic-
tion accuracy was obtained for the same data using 
17 the most signiﬁ  cantly expressed genes), the set 
of signiﬁ  cantly enriched pathways showing the 
strongest correlation to prostate tumour expression 
patterns is likely to be of greater biological interest. 
Such pathways might indicate one or more 
processes as acting drivers related to prostate 
Table 3. The top 20 signiﬁ  cantly enriched pathways found for the set of signiﬁ  cantly differentially-expressed genes 
identiﬁ  ed using PSLM (Supplementary Table 2), together with the predictive accuracies in the test datasets.
Pathway  p-value  # of   Accuracy in  Accuracy in   Pathway Name
ID    Genes  the Singh  the Stuart    
      testing data  testing data
03010 0  32  0.784  0.693  Ribosome
04010  3.33E-16  26  0.784  0.455  MAPK signaling pathway
04810  5.66E-14  22  0.745  0.602  Regulation of actin cytoskeleton
00230 6.13E-14  21  0.686  0.591  Purine  metabolism
04910  1.41E-13  21  0.804  0.739  Insulin signaling pathway
04514  3.08E-13  20  0.824  0.614  Cell adhesion molecules (CAMs)
04020 4.49E-13  20  0.784  0.602  Calcium  signaling  pathway
04510 1.22E-12  19  0.765  0.58  Focal  adhesion
00190 1.31E-10  16  0.843  0.693  Oxidative  phosphorylation
04664  1.17E-09  14  0.686  0.5  Fc epsilon RI signaling pathway
04540 1.17E-09  13  0.706  0.5  Gap  junction
04060  3.16E-09  13  0.725  0.591  Cytokine-cytokine receptor interaction
00240 3.94E-09  13  0.843  0.705  Pyrimidine  metabolism
00480 4.95E-09  13  0.784  0.591  Glutathione  metabolism
04520 5.33E-09  13  0.784  0.466  Adherens  junction
04070  4.75E-08  11  0.686  0.739  Phosphatidylinositol signaling system
04080  7.64E-08  11  0.706  0.614  Neuroactive ligand-receptor interaction
04670  7.75E-08  11  0.784  0.602  Leukocyte transendothelial migration
04512 1.33E-07  10  0.765  0.693  ECM-receptor  interaction
04360 1.58E-07  10  0.745  0.523  Axon  guidance
cancer. Furthermore, this enables a large set of 
genes or probesets, identiﬁ  ed by the integrative 
analysis testing for differential expression, to be 
considered in the subsequent pathway analysis and 
predictive modelling. Hence this pathway analysis 
approach may reduce the concern over the vari-
ability in the speciﬁ  c genes given in the top ranking 
by any one dataset or any one analysis. There 
appears to be more consistency in the represented 
pathways across the two integrative methods than 
in the top genes. It should be noted that there are 
also other carefully curated pathway sets (Subra-
manian et al. 2005) and gene sets, such as gene 
ontology (Harris et al. 2004), that could be used 
for this purpose. We did not explore them, since 
our focus was on comparing the performance of 
PLM and PSLM rather than on identifying the best 
pathways for predicting prostate cancer. In this 
study, we just focused on the prediction power of 
individual pathways. It will be also interesting to 
evaluate the interactions among pathways and their 
effects on cancer prediction.
In this paper, we have used a probe-level based 
statistic (Bolstad, 2004; Bolstad, 2005) to deﬁ  ne 
an effect size for the purpose of data integration. Cancer Informatics 2006: 2 299
Pathway-based Models for Prostate Cancer Prediction
The test statistic treats probes as replicates which 
might lead to a biased variance estimate for the t 
statistic, which in turn will have impact on the 
effect size deﬁ  ned at the probe-level. This issue 
warrants further investigation in the future. For 
example, one may redeﬁ  ne the effect size using a 
correction factor similar to the factor proposed by 
Hedges and Olkin (1985) in the case of the stan-
dardized mean difference effect measure.
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